These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 683404)

  • 1. Myoinositol--a uremic neurotoxin?
    Blumberg A; Esslen E; Bürgi W
    Nephron; 1978; 21(4):186-91. PubMed ID: 683404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental studies on pathogenesis and progression of uremic neuropathy in rats. II. Is plasma myoinositol a uremic neurotoxin?
    Onishi S; Kawasaki T; Hamada K
    Bull Osaka Med Sch; 1986 Oct; 32(2):66-72. PubMed ID: 3427262
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma-myoinositol concentrations in uraemic neuropathy.
    Reznek RH; Salway JG; Thomas PK
    Lancet; 1977 Mar; 1(8013):675-6. PubMed ID: 66475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma, red cell and cerebrospinal fluid concentrations of myoinositol in patients with severe chronic renal failure.
    Servo C; Bardy A; Pasternack A; Pitkänen E
    Ann Clin Res; 1976 Dec; 8(6):374-7. PubMed ID: 1008476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of glomerular filtration rate on uremic polyneuropathy.
    Savazzi GM; Migone L; Cambi V
    Clin Nephrol; 1980 Feb; 13(2):64-72. PubMed ID: 6244910
    [No Abstract]   [Full Text] [Related]  

  • 6. Raised plasma-myoinositol levels in uraemia and experimental neuropathy.
    Clements RS; DeJesus PV; Winegrad AI
    Lancet; 1973 May; 1(7813):1137-41. PubMed ID: 4123536
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis.
    Salvati F; Liani M
    Int J Artif Organs; 2001 Mar; 24(3):131-5. PubMed ID: 11314805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in motor nerve conduction velocity in normal and uremic patients.
    Kominami N; Tyler HR; Hampers CL; Merrill JP
    Arch Intern Med; 1971 Aug; 128(2):235-239. PubMed ID: 4327548
    [No Abstract]   [Full Text] [Related]  

  • 9. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 10. [Anti-inflammatory action of myoinositol in renal insufficiency].
    Rysz J; Bartnicki P; Błaszczak R; Kujawski K; Ciałkowska-Rysz A; Olszewski R; Markuszewski L
    Pol Merkur Lekarski; 2006 Feb; 20(116):180-3. PubMed ID: 16708635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "unphysiology" of dialysis: a major cause of dialysis side effects?
    Kjellstrand CM; Evans RL; Petersen RJ; Shideman JR; von Hartitzsch B; Buselmeier TJ
    Kidney Int Suppl; 1975 Jan; (2):30-4. PubMed ID: 1057690
    [No Abstract]   [Full Text] [Related]  

  • 12. Search for the uremic toxin. Decreased motor-nerve conduction velocity and elevated parathyroid hormone in uremia.
    Avram MM; Feinfeld DA; Huatuco AH
    N Engl J Med; 1978 May; 298(18):1000-3. PubMed ID: 205786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes.
    Greene DA; De Jesus PV; Winegrad AI
    J Clin Invest; 1975 Jun; 55(6):1326-36. PubMed ID: 124320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Velocity of maximal motor nerve conduction in polyneuropathies of uremic patients subjected to various types of hemodialysis for varying periods of time: values and limitations].
    Savazzi GM; Arisi L; Bignardi L; Rossi E; Cambi V; Allegri L
    Riv Neurol; 1976; 46(1):25-35. PubMed ID: 1013604
    [No Abstract]   [Full Text] [Related]  

  • 15. Accumulation of myoinositol in plasma and red cells of diabetic patients.
    Servo C
    Acta Med Scand; 1977 Jan; 201(1-2):59-62. PubMed ID: 835372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremic neuropathy: evidence of middle molecule toxicity.
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):45-51. PubMed ID: 687020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid sorbitol and myoinositol in diabetic polyneuropathy.
    Servo C; Bergström L; Fogelholm R
    Acta Med Scand; 1977; 202(4):301-4. PubMed ID: 920249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in polyol levels in cerebrospinal fluid and serum in diabetic patients.
    Servo C; Pitkänen E
    Diabetologia; 1975 Dec; 11(6):575-80. PubMed ID: 1205026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Uremic neuropathies. Comparative study of the velocity of motor and nerve conduction during predialysis, hemodialysis and postransplantation periods].
    Fernández González F
    Arch Neurobiol (Madr); 1976; 39(1):15-36. PubMed ID: 776116
    [No Abstract]   [Full Text] [Related]  

  • 20. [Uremic neuropathy--I. Is uremic neuropathy related to patient age, duration of nephropathy and dialysis treatment?].
    Jedras M; Zakrzewska-Pniewska B; Wardyn K; Switalski M
    Pol Arch Med Wewn; 1998 Jun; 99(6):452-61. PubMed ID: 10085699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.